Akari醫療公共 AKTX 深 滬
已收盤 10-24 16:00:00 美东时间
0.74
+0.001
+0.14%
華盛通- 最 高0.77
- 今 開0.7389
- 成交量 8.25万股
- 最 低 0.73
- 昨 收 0.739
- 總市值 2413.49万
- 52周最高 2.91
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 0.5714
- 委 比 -57.26%
- 總股本 3261.47万
- 歷史最高 2380.00
- 量 比 1.01
- 振 幅 5.41%
- 歷史最低 0.5714
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akari Therapeutics Appoints Kameel Farag as Interim CFO
The latest announcement is out from Akari Therapeutics ( ($AKTX) ). On October ...
10-24 05:21
Akari Therapeutics Announces Launch of CEO Corner Platform
Akari Therapeutics launched its CEO Corner platform, featuring President and CEO Abizer Gaslightwala, to provide deeper insights into company developments and pipeline progress. The platform aims to offer stakeholders additional perspectives beyond press releases, fostering clearer communication about the company's vision and goals. Akari focuses on developing innovative ADCs, with its lead candidate AKTX-101 targeting Trop2 receptors and deliver...
10-22 13:05
Akari Therapeutics Announces A $2.5M Registered Direct Offering Of 3,125,000 American Depositary Shares At $0.80 Per ADS
Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the
10-15 20:37
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
Akari Therapeutics announced that its abstract on a novel splicing-targeted ADC payload has been accepted for oral presentation at the 40th Annual SITC Meeting in November 2025. The payload, PH1, modulates RNA splicing in cancer cells, inducing cell death and immune activation, with potential synergy with checkpoint inhibitors. Akari's lead candidate, AKTX-101, has shown significant activity and prolonged survival in preclinical studies. The pres...
10-03 13:30
Akari Therapeutics Completes August 2025 Notes Offering
The latest announcement is out from Akari Therapeutics ( ($AKTX) ). Akari Thera...
09-30 05:32
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Akari Therapeutics announced preclinical data showing potential of its ADC payload PH1 in treating tumors driven by alternative splicing, such as AR-V7 in prostate cancer. AR-V7 is linked to metastatic castration-resistant prostate cancer (mCRPC) progression. PH1 suppresses AR-V7 expression in hormone-refractory models and shows benefits alone or combined with ARPIs, potentially slowing resistance and tumor progression. Akari aims to develop PH1 ...
09-24 12:45
Akari Therapeutics Files Provisional Patent Application With USPTO Covering ADC Platform Using Akari's Spliceosome Payload PH1 For Treating Cancer By Modulating Alternative Splicing Within Cancer Cells
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States
09-17 20:53
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
Akari Therapeutics filed a provisional patent application with the USPTO for its ADC platform using the PH1 payload to treat cancer by modulating alternative splicing. PH1, a novel Thailanstatin analog, disrupts alternative splicing drivers in cancer cells, targeting tumor survival and growth. This application enhances Akari's intellectual property and potential for developing innovative therapies across various cancers. The company plans to adva...
09-17 12:45
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Akari Therapeutics的CEO Abizer Gaslightwala将在2025年9月8日至10日在纽约举行的H.C. Wainwright全球投资会议上发表演讲，并在会议期间与投资者进行一对一会谈。公司专注于开发下一代载荷抗体药物偶联物（ADCs），其领先候选药物AKTX-101使用新型PH1载荷，通过干扰癌细胞的RNA剪接机制诱导癌细胞死亡并激活免疫反应，展现出显著的临床前活性。公司正推进该药物的开发，并探索其与免疫检查点抑制剂的协同作用。演讲视频网络直播将可在公司网站上观看。
09-05 10:45
